Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 3 评价冻干人纤白蛋白微球注射液治疗难治性血小板减少的有效性和安全性的Ⅲ期临床试验
[Translation] Phase III clinical trial to evaluate the efficacy and safety of freeze-dried human fibrillary albumin microsphere injection in the treatment of refractory thrombocytopenia
在Ⅱb期基础上,进一步观察冻干人纤白蛋白微球治疗难治性血小板减少的有效性和安全性,为本品的注册审查申请提供依据。
[Translation] Based on Phase IIb, further observations will be made on the efficacy and safety of freeze-dried human fibrillary albumin microspheres in the treatment of refractory thrombocytopenia, providing a basis for the registration review application for this product.
100 Clinical Results associated with Kuaiyi Biological Medicine Technology (Kunshan) Co., Ltd.
0 Patents (Medical) associated with Kuaiyi Biological Medicine Technology (Kunshan) Co., Ltd.
100 Deals associated with Kuaiyi Biological Medicine Technology (Kunshan) Co., Ltd.
100 Translational Medicine associated with Kuaiyi Biological Medicine Technology (Kunshan) Co., Ltd.